JPS58103301A - Powdery aerosol suspension liquid - Google Patents

Powdery aerosol suspension liquid

Info

Publication number
JPS58103301A
JPS58103301A JP20135181A JP20135181A JPS58103301A JP S58103301 A JPS58103301 A JP S58103301A JP 20135181 A JP20135181 A JP 20135181A JP 20135181 A JP20135181 A JP 20135181A JP S58103301 A JPS58103301 A JP S58103301A
Authority
JP
Japan
Prior art keywords
powder
liquefied
liquefied propellant
propellant
dispersing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP20135181A
Other languages
Japanese (ja)
Inventor
Takahiro Shinosawa
篠沢 孝紘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Aerosol Industry Co Ltd
Original Assignee
Toyo Aerosol Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Aerosol Industry Co Ltd filed Critical Toyo Aerosol Industry Co Ltd
Priority to JP20135181A priority Critical patent/JPS58103301A/en
Publication of JPS58103301A publication Critical patent/JPS58103301A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26Aluminium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Abstract

PURPOSE:To provide the titled liquid storable for a long time without causing the lowering of redispersibility, and useful as a cosmetic and quasi-drug, by dispersing a specific substrate powder composed of silicon dioxide, magnesium oxide and aluminum oxide and fine powder of solid drug in a specific liquefied propellant. CONSTITUTION:The objective powdery aerosol suspension liquid is prepared by dispersing (A) 5-20(wt)% substrate powder having a pH of 6-8 and consisting of 42-64% silicon dioxide, 26-35% magnesium oxide and 1-20% aluminum oxide and (B) 0.2-15% fine powder of solid drug insoluble in the liquefied propellant (e.g. hydrocortisone, predonizolone, etc.) in (C) a liquefied propellant composed of 50-80% freon gas and 10-35% liquefied petroleum gas and/or 10-35% dimethyl ether. The use of the substrate enables the formation of homogeneous suspension easily only by turning the container upside down several times or shaking, even after a long-term storage.

Description

【発明の詳細な説明】 本発明は化粧晶又#i医鵜部外品に遣する粉末エアゾー
ル―濁液゛に係るもので、液化噴射剤と不溶のlI廖装
粉末成分を拳濁化剤又は界面活性剤を用いて液化噴射剤
に懸濁分散させて耐圧容器内に充填し噴霧を行なうこと
は従来より知られている。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a powder aerosol-turbid liquid for use in cosmetic crystals or quasi-medical products, in which a liquefied propellant and an insoluble liquid powder component are used as a clouding agent. Alternatively, it is conventionally known to suspend and disperse a liquefied propellant using a surfactant, fill it in a pressure container, and perform spraying.

例えばレシチン、ラノリン、コレステロール又ハこれら
の誘導体を高級脂肪酸のエステルに溶解したものを用い
てブタン、フロン等の液化噴射剤に不溶の固形薬品微粉
末を上記液化噴射剤に分ikさせる方法(勢公昭40−
28956号)。又はIfLB#lO以下であり且フロ
ンガス等の液化噴射剤に可溶、である液状非イオン界面
活性剤を基剤微粉末とともに上記液化噴射剤中に龜濁さ
電る方法←特公昭36−14397号);又はブタン、
ペンタン、フロン等の液化噴射剤に可溶であるリン酸エ
ステル鋼と縦索原子11〜30個を有し且室温で液状の
直鎖あるいは側鎖高級アルコール及び天然リン脂肪によ
り微粉末状医療物質を上記液化噴射剤に懸濁させる方法
←特公昭42−14804号)。又は多価アルコールの
長鎖脂肪酸による部分エステルの了セチル化物で液状の
懸濁化剤を用いて微細粉末とフロン、液化石油ガス等の
液化噴射剤を懸濁する方法(411公昭41−409号
)等が知られている。しかしながら以上の如き従来公知
の方法では凝集を生じるとか、再分散性が悪くなる等エ
アゾール製品として種々の好ましくない結果を生じ易い
ものであった。即ち液化噴射剤として、フロンガスに液
化石油ガス又はジメチルエーテル又はその双方を加えて
使用することが行なわれている。これはオゾンMt−破
壊するといわれるフロンガスの使用量¥rlII!少す
せるととも&:IiI+価なフロンカスに加えて廉価な
液化石油カス、ジメチルエーテルを混合使用するもので
ある。しかしながら噴射剤に液化石油カス又はジメチル
エーテルを使用し、これに従来公知の基剤粉末を共存さ
せて懸濁液を形成しようとすると懸濁粒子の沈降が早く
、浮遊又は再分散性が悪く凝集を生じ、均一な噴霧を困
−にするとともにパルプ、アクチェーターの詰りを生じ
易いものとなり、又薬剤成分の効力にも悪影響を及ぼす
ものとなる。
For example, a method of separating solid drug fine powder insoluble in liquefied propellants such as butane and chlorofluorocarbons into the liquefied propellant using lecithin, lanolin, cholesterol, or their derivatives dissolved in esters of higher fatty acids. Kosho 40-
No. 28956). Or, a method in which a liquid nonionic surfactant that is less than IfLB#lO and is soluble in a liquefied propellant such as fluorocarbon gas is added to the liquefied propellant together with a base fine powder←Japanese Patent Publication No. 36-14397 ); or butane;
A finely powdered medical substance made of phosphate ester steel that is soluble in liquefied propellants such as pentane and chlorofluorocarbons, linear or side chain higher alcohols that have 11 to 30 longitudinal atoms and is liquid at room temperature, and natural phosphorus fat. (Japanese Patent Publication No. 42-14804). Alternatively, a method of suspending fine powder and a liquefied propellant such as fluorocarbons or liquefied petroleum gas using a liquid suspending agent made of a cetylated partial ester of a long-chain fatty acid of a polyhydric alcohol (No. 411 Kosho 41-409) ) etc. are known. However, the conventionally known methods described above tend to produce various undesirable results as aerosol products, such as agglomeration and poor redispersibility. That is, as a liquefied propellant, liquefied petroleum gas, dimethyl ether, or both are added to fluorocarbon gas and used. This is the amount of CFC gas used that is said to destroy ozone Mt. It uses a mixture of inexpensive liquefied petroleum scum and dimethyl ether in addition to &:IiI+ fluorocarbon gas. However, when attempting to form a suspension by using liquefied petroleum scum or dimethyl ether as a propellant and coexisting with a conventionally known base powder, the suspended particles settle quickly and have poor floating or redispersibility, resulting in agglomeration. This makes uniform spraying difficult, tends to cause clogging of the pulp and actuator, and has an adverse effect on the efficacy of the drug ingredients.

特に懸濁させる固形薬品微粉末が多い場合はバルブ及び
アクチー−ターの詰りは更に著るしいものとなる。上記
従来例の粉末エアゾール又は従来公知の粉末エアゾール
に使用する粉末は、メルク、カオリン、ベントナイト類
その他極めて多くの天然成分を含有す′るものが用いら
れているが、これら基剤粉末に目的固形薬品微粉末や、
助剤、エステル類、凝集を防ぐための界面活性剤を共存
させ、コtL Cフロンガスを噴射剤として用いるもの
であった。噴射剤にフロンガスケ使用すると前述の如く
オゾン層破壊の問題を生じ又^価となる欠点を生じ、ジ
メチルエーテル、液化石油ガス等を用いると前述の如(
凝集が生じ、再分散性が總化し、これらの点を改善する
ため界面活性剤を添加すると多少上記欠点の改良はなさ
れるが、新たにペタツキを生じ使用感を悪化させるもの
となる。
In particular, when there is a large amount of fine solid chemical powder suspended, clogging of the valve and actuator becomes even more serious. The powder used in the above-mentioned conventional powder aerosol or the conventionally known powder aerosol contains Merck, kaolin, bentonite, and many other natural ingredients. Fine chemical powder,
Auxiliary agents, esters, and a surfactant to prevent agglomeration were coexisting, and CFC gas was used as a propellant. If fluorocarbon gas is used as a propellant, it will cause the problem of ozone layer depletion as mentioned above, and it will also have the disadvantage of being expensive. If dimethyl ether, liquefied petroleum gas, etc. are used,
Agglomeration occurs and redispersibility becomes poor.Addition of a surfactant to improve these problems somewhat improves the above-mentioned drawbacks, but it also causes stickiness and worsens the feeling of use.

本発明は上記欠点を改良するため研究を重ねた結果成さ
れたものであって基剤粉末として二酸化珪素42〜64
wt%、酸化マグネジ9ム26〜35wt%および酸化
アルミニュ9ムl〜2゜wt%から成るpH6〜8の基
剤粉末を使用することにより70′ンガスのみで番jな
く、フロンカスと液化石油ガス又はジメチルエーテル又
はその双方を噴射剤として興用しても凝集を生じたり、
再分散性を悪化させることな(、長期の保存に於ても安
定で変質等を住じることがなく、父上記組成に目的主薬
、助剤等を加えてもその効果に何等変化のないことが確
認された。これらの効果から本発明は化粧品、1桑部外
品用の粉末エアゾール製品に用いる場合特に有効である
。父上記基剤粉末は粉末エアゾール懸濁液全量に対して
1〜20wt%の範囲で用いる。上記基剤粉末は粒径1
00μ以下、好ましくは5〜35μのものを用い、剤形
全量に対して20ft%以下好ましくは2〜8wt%と
する。70ンカス、液化石油ガス、ジメチルエーテル等
の液化石油ガスに不溶の剤形形成用目的固形薬品徽粉末
としては、その形成目的にメつで全く異なるものを用い
るが、−例としてはハイドロコチゾン、プレドニゾロン
、デキサメサゾン、酸化鉄、硫酸フラジオマイシン、ア
ルミニュウム塩類の収斂効果を有するもの等があり、o
、 2−15 W t%使用し通常100μ以下、好ま
しく4は5〜35μの粒径を持つものが良い。又フロン
ガスには、ジクロルジフルオルメタン、ジクロルテトラ
フルオルエタン、トリクロルモノフルオルメタン略を用
い激化石油カス又はジメチルエーテルと混合して用いる
ことができる。この混合比率はフロンカス50〜sow
t%、激化石油カス10〜35wt%又はジメチルエー
テルlO〜35wt%又はその双方とTる。この噴射剤
と基剤粉末および薬品微粉末を、エアゾール容器内に充
填し、良く振盪することにより混合する。こうして得ら
れた懸濁液は長期間放置しても沈降、浮上又は凝集塾の
再分散性不良状11を生ずることがなく、又パルプ詰り
、アクチェーターの詰り等を生じることがなく長期間放
置後もエアゾール容器を数回転倒又は1&處するのみで
容易に均一な懸濁液を形成することができた。又エアゾ
ール容器の腐蝕を生じることもなかった。
The present invention was achieved as a result of repeated research in order to improve the above-mentioned drawbacks.
By using a base powder with a pH of 6 to 8 consisting of 26 to 35 wt% of magnesium oxide and 9 to 2 wt% of aluminum oxide, it is possible to use only 70' gas and not fluorocarbon gas and liquefied petroleum gas. Or, even if dimethyl ether or both are used as a propellant, agglomeration may occur.
It does not deteriorate redispersibility (it is stable and does not undergo deterioration even during long-term storage, and there is no change in its effectiveness even if the target active ingredient, auxiliary agents, etc. are added to the above composition). From these effects, the present invention is particularly effective when used in powdered aerosol products for cosmetics and other products. Used in a range of 20 wt%.The above base powder has a particle size of 1
00μ or less, preferably 5 to 35μ, and the amount is 20ft% or less, preferably 2 to 8wt% based on the total amount of the dosage form. As the solid drug powder for forming a dosage form insoluble in liquefied petroleum gas such as liquefied petroleum gas, dimethyl ether, etc., completely different substances are used depending on the purpose of its formation; examples include hydrocotisone, These include prednisolone, dexamethasone, iron oxide, fradiomycin sulfate, and those that have the astringent effect of aluminum salts.
, 2-15 Wt% is used, and the particle size of 4 is usually 100μ or less, preferably 5-35μ. Further, as the fluorocarbon gas, dichlorodifluoromethane, dichlorotetrafluoroethane, or trichloromonofluoromethane can be used by mixing with evaporated petroleum scum or dimethyl ether. This mixing ratio is Froncas 50 ~ sow
t%, 10 to 35 wt% of aggravated petroleum scum, or 10 to 35 wt% of dimethyl ether, or both. This propellant, base powder, and fine drug powder are filled into an aerosol container and mixed by shaking well. The suspension obtained in this way does not cause sedimentation, flotation, or poor redispersion of flocculation even if left for a long period of time, and does not cause pulp clogging or actuator clogging, etc. even after being left for a long period of time. It was also possible to easily form a uniform suspension by simply inverting the aerosol container several times. Further, no corrosion of the aerosol container occurred.

下記実施例に於て再分散状態、とは、45℃で6ケ月間
放置後に於て粉末の分散状態を観察したものであって、 ◎ 均一に分散しているもの △ やや凝集の傾向にあるもの X  部分的に強い凝集体を生じたちのXX  凝集の
強いもの を示している。
In the examples below, the redispersion state refers to the state of dispersion of the powder observed after it was left at 45°C for 6 months. ◎ Uniformly dispersed △ Slight tendency to agglomerate Thing X Partially forms a strong agglomerate XX Indicates a strongly agglomerated substance.

又バルブ詰りとは、45℃、fi[B、5%の状障に於
て7日サイクルで6ケ月間噴射を行ないパルプ&:粘り
を生じないものを「ナシ」とし、詰りの発生したものを
「発生」とした。
In addition, valve clogging refers to pulp &: those that do not become sticky after being injected for 6 months at 45°C, fi [B, 5% condition, and do not produce stickiness, and those that are clogged. was defined as an “occurrence”.

又腐蝕性とは45℃で6ケ月間保存し肉眼観察で腐蝕の
ないものを「ナシ」とし腐蝕の発生しているものを少量
のものも含めて1発生」とした。
Corrosion property was defined as ``no'' if there was no corrosion observed with the naked eye after storage at 45°C for 6 months, and ``1'' if corrosion occurred, including a small amount.

又実施例中1〜3.7〜9.12〜14.17〜19.
22〜24は外用薬、4〜6.1O111゜15.16
.20.21.25〜34、は制汗剤、35.36はボ
ディパウダである。従来品中1〜番はボディパウダー、
5〜8は制汗剤である。又粉末基剤のイ〜ホの区分は下
記割合によるものである。
In addition, 1 to 3.7 to 9.12 to 14.17 to 19.
22-24 are external medicines, 4-6.1O111°15.16
.. 20.21.25-34 are antiperspirants, 35.36 are body powders. Among the conventional products, numbers 1 to 1 are body powders,
5 to 8 are antiperspirants. The classification of powder bases A to E is based on the following proportions.

イ   ロ  ハ  ニ  ホ 二酸化珪素       54 60 60 64 4
f5酸化マグネシウム   26 30 35 35 
35酸化アルミニユウム   20 10  5  1
20父上記配合及び実権例中に用いる数値はWt嗟を示
している。
i ro ha ni silicon dioxide 54 60 60 64 4
f5 magnesium oxide 26 30 35 35
35 aluminum oxide 20 10 5 1
20 The numerical values used in the above formulations and practical examples indicate Wt.

Claims (1)

【特許請求の範囲】[Claims] 二酸化珪素42〜64wt%、酸化マグネシウム26〜
35ft%および酸化アルj=エクムl〜20wt%か
ら成るpH6〜Bの基剤粉末管5〜20wt%と、フロ
ンガス5o〜aowt%に電化石油ガス10゛〜35w
t%又はジメ、チルエーテル10〜sawt%又紘その
双方から成る液化噴射剤と、こt)液化噴射剤に不溶の
剤#1#成用台的m拳薬品微粉末0.2〜16  wt
%とから成り、この鶏晶微験車と上記基剤粉末を上記液
化噴射剤中に懸濁分散させることを特徴とする粉末エア
ゾール懸濁液。
Silicon dioxide 42~64wt%, magnesium oxide 26~
5-20 wt% base powder tube of pH 6-B consisting of 35 ft% and 20 wt% of aluminum oxide, and 5-20 wt% of fluorocarbon gas and 10-35 w of electrified petroleum gas.
A liquefied propellant consisting of 10% to 10% to 10% to 10% to 16% by weight of methyl ether and 10% to 100% by weight of ethyl ether, and t) A liquefied propellant insoluble in the liquefied propellant.
%, the powder aerosol suspension is characterized by suspending and dispersing the above-mentioned liquefied microscopic wheel and the above-mentioned base powder in the above-mentioned liquefied propellant.
JP20135181A 1981-12-14 1981-12-14 Powdery aerosol suspension liquid Pending JPS58103301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP20135181A JPS58103301A (en) 1981-12-14 1981-12-14 Powdery aerosol suspension liquid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20135181A JPS58103301A (en) 1981-12-14 1981-12-14 Powdery aerosol suspension liquid

Publications (1)

Publication Number Publication Date
JPS58103301A true JPS58103301A (en) 1983-06-20

Family

ID=16439588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20135181A Pending JPS58103301A (en) 1981-12-14 1981-12-14 Powdery aerosol suspension liquid

Country Status (1)

Country Link
JP (1) JPS58103301A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63250325A (en) * 1987-04-07 1988-10-18 Shinagawa Nenryo Kk Antimicrobial composition for spray
JPH01143819A (en) * 1987-11-27 1989-06-06 Shiseido Co Ltd Aerosol composition
JPH02191693A (en) * 1988-06-20 1990-07-27 Shiseido Co Ltd Aerosol composition
WO2001022926A1 (en) * 1999-09-30 2001-04-05 L'oreal Cosmetic composition comprising nanoparticles containing alumina
FR2814067A1 (en) * 2000-09-20 2002-03-22 Oreal COMPOSITION PACKED IN AN AEROSOL DEVICE, COMPRISING ALUMINA NANOPARTICLES

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63250325A (en) * 1987-04-07 1988-10-18 Shinagawa Nenryo Kk Antimicrobial composition for spray
JPH01143819A (en) * 1987-11-27 1989-06-06 Shiseido Co Ltd Aerosol composition
JPH02191693A (en) * 1988-06-20 1990-07-27 Shiseido Co Ltd Aerosol composition
WO2001022926A1 (en) * 1999-09-30 2001-04-05 L'oreal Cosmetic composition comprising nanoparticles containing alumina
FR2814067A1 (en) * 2000-09-20 2002-03-22 Oreal COMPOSITION PACKED IN AN AEROSOL DEVICE, COMPRISING ALUMINA NANOPARTICLES
EP1190701A1 (en) * 2000-09-20 2002-03-27 L'oreal Composition, packaged in an aerosol device, comprising alumina nanoparticles

Similar Documents

Publication Publication Date Title
US4450151A (en) Powder aerosol composition
AU577663B2 (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
US6743756B2 (en) Suspensions of particles in non-aqueous solvents
JP3468767B2 (en) Medicine
US4211781A (en) Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
CA2257841C (en) Medicinal aerosol formulations of formoterol
US5741517A (en) Water-containing liposome system
US5310734A (en) Phospholipid composition
Tzou et al. Drug form selection in albuterol‐containing metered‐dose inhaler formulations and its impact on chemical and physical stability
JPH07506598A (en) Solid additive system dispersible in aqueous medium and method for producing the same
JP6417181B2 (en) Emulsion composition for aerosol preparation and aerosol agent
JPH06211620A (en) Powdery cosmetic
JPS58103301A (en) Powdery aerosol suspension liquid
US5438044A (en) Phospholipid composition
CA2073096C (en) Phospholipid composition
MXPA02005317A (en) Phospholipidic composition and use of same.
JPS6141893B2 (en)
JPH0244870B2 (en) FUNMATSUGANJUSUISEIEAZOORUSOSEIBUTSU
JP2772073B2 (en) Powder aerosol composition
US4018888A (en) Amine-stabilized dry powder aerosol antiperspirant compositions and method of preparation
JPS6317112B2 (en)
US3551558A (en) Therapeutical aerosol composition and preparation thereof
JPH0242811B2 (en)
JPH0244350B2 (en)
JP3137251B2 (en) Antibacterial and deodorant spray